The relationship between inflammatory markers and spirometric parameters in ACOS, Asthma, and COPD

• Published in: The Journal of asthma Vol. 57; no. 12; pp. 1273 - 1279
• Main Authors: Uzan, Gulfidan Cakmak, Borekci, Sermin, Doventas, Yasemin Erdogan, Koldas, Macit, Gemicioglu, Bilun
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01-12-2020
• Subjects: ACOS; ADAM 33; ADAM Proteins - blood; ADAM Proteins - immunology; Adult; Aged; Aged, 80 and over; Asthma; Asthma - blood; Asthma - diagnosis; Asthma - immunology; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome - blood; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome - diagnosis; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome - immunology; Biomarkers - blood; COPD; Cross-Sectional Studies; cys-LTs; Diagnosis, Differential; Dinoprostone - blood; Dinoprostone - immunology; Female; Humans; inflammation; Inflammation - blood; Inflammation - diagnosis; Inflammation - immunology; Inflammation Mediators - blood; Inflammation Mediators - immunology; interleukin; Interleukin-5 - blood; Interleukin-5 - immunology; Male; matrix metalloprotease; Middle Aged; prostaglandin; Prostaglandin D2 - blood; Prostaglandin D2 - immunology; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - immunology; Spirometry; Young Adult; matrix metalloprotease; inflammation; prostaglandin; cys-LTs; ADAM 33; ACOS; interleukin; Asthma; COPD
• ISSN: 0277-0903; 1532-4303
• DOI: 10.1080/02770903.2019.1652644

Objective: The inflammatory mechanisms underpinning asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have not been fully elucidated. Here, we examined the levels of cysteinyl leukotrienes (cys-LTs), prostaglandin D2 (PG-D2), prostaglandin E2 (PG-E2), interleukin 5 (IL-5), and a disintegrin and metalloprotease domain (ADAM 33) in ACOS patients to determine the relationship between levels of these inflammatory markers and pulmonary functions.
Methods: Blood samples were obtained from asthma, COPD, and ACOS patients who received combined therapy and were stable for the last month to measure cys-LTs, PG-D2, PG-E2, IL-5, and ADAM33 levels. Differences between groups and their correlations with pulmonary function tests were evaluated.
Results: In total, 24 ACOS, 27 asthma, and 35 COPD patients were included. . PG-D2 levels were higher in ACOS (120.9 ± 117.2 ng/L) and asthma (119.6 ± 111.7 ng/L) patients than in COPD (82.6 ± 46.7 ng/L) patients (p = 0.036 and p = 0.038, respectively). In ACOS patients, PG-D2, cys-LTs, and ADAM33 levels were negatively correlated with FEV1/FVC% values (p = 0.021, p = 0.008, and p = 0.028, respectively). In COPD patients, a negative correlation was detected between PG-E2 and FEV1/FVC% (p = 0.007), whereas positive correlations were detected between IL-5 and pulmonary function tests, including FVC, FVC%, FEV1, FEV1%, FEF25-75, and FEF25-75% (p = 0.047, p = 0.005, p = 0.002, p = 0.002, p = 0.010, and p = 0.005, respectively). In asthma patients, cys-LTs levels were negatively correlated with FEV1 and FEF25-75 values (p = 0.045 and p = 0.037, respectively).
Conclusions: PG-D2 levels may be a valuable biomarker to differentiate COPD in asthma and ACOS patients.